ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed... ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
- Mechanism
- Curator reviewed
ATL1101 is an antisense compound targeting Insulin-like Growth Factor-I Receptor, or IGF-1R. Researchers believe that IGF-1R plays a pivotal role in the regulation of cell growth in psoriasis. Study shows that antisense molecules successfully inhibit production of IGF-1R and normalize the skin architecture in human psoriasis skin samples grafted onto mice.
- Primary indication
- Investigated for use/treatment in psoriasis and psoriatic disorders.Curator reviewed
- Code names
- ATL1101
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with ATL1101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account